Further information on these and other current trials can be obtained by visiting either: • US National Library of Medicine - Clinical Trials database HERE • UK National Institute for Healthcare Research Be Part of Research database HERE Research is ongoing to develop a strong evidence base to widen the i neuroendocrine cancer primary sites, such as lung, and also other gra There are also studies using other radioligands, for example Targeted There are 3 forms of RLT that may be used in neuroendocrine cancers • Iodine-131 meta-iodobenzylguanidine (I-131 MIBG) primarily used f • Yttrium90 (used less frequently for RLT, but the radionuclide may be • Lutetium (177Lu) oxodotreotide (Lutathera®) main agent currently u Only Lutetium (177Lu) oxodotreotide is currently licensed (2023) withi differentiated (grade 1 or grade 2), somatostatin receptor-positive gas However MIBG is accessible for eligible patients.
Click here to read about what Radioligand Therapy is from the Health Policy Partnership
Made with FlippingBook - Share PDF online